Pleural Effusion
Buildup of fluid between the layers of tissue that line the lungs and chest cavity, commonly causing shortness of breath and chest pain.
Emergency Management: Tension hydrothorax causing hemodynamic instability requires emergent large-volume therapeutic thoracentesis. Avoid removing >1.5 liters in a single setting to prevent re-expansion pulmonary edema.
A pleural effusion is an abnormal accumulation of fluid in the pleural space, the potential space between the visceral and parietal pleura. It is a manifestation of an underlying disease rather than a primary disease itself.
Detailed Overview
Normally, 10-20 mL of fluid lubricates the pleural space, continuously produced by the parietal pleura and absorbed by lymphatic stomata. An effusion develops when fluid production exceeds absorption. Effusions are broadly classified into transudates (resulting from systemic imbalances in hydrostatic or oncotic pressure) and exudates (resulting from local pleural inflammation or altered capillary permeability). Identifying the underlying cause via thoracentesis and fluid analysis using Light's criteria is critical for guiding therapy.
Epidemiology & Demographics
Affects approximately 1.5 million people annually in the United States. Congestive heart failure is the most common cause of transudative effusions, while pneumonia and malignancy are the leading causes of exudative effusions.
Etiological Mechanism
Transudative causes: Heart failure (most common), cirrhosis, nephrotic syndrome. Exudative causes: Parapneumonic (bacterial pneumonia), malignancy (lung, breast, lymphoma), pulmonary embolism, tuberculosis, connective tissue diseases (rheumatoid arthritis, lupus).
Primary Causes
Elevated pulmonary capillary hydrostatic pressure, decreased plasma oncotic pressure, increased pleural capillary permeability, lymphatic obstruction, or movement of fluid from the peritoneal cavity (hepatic hydrothorax).
The pleural fluid turnover is governed by Starling forces. In a healthy state, the hydrostatic pressure pushing fluid out of parietal capillaries is balanced by lymphatic drainage. Transudates form when systemic hydrostatic pressure is profoundly elevated (e.g., LVEDP > 15 mmHg in CHF) or oncotic pressure is depressed (e.g., Albumin < 2.5 g/dL). Exudates occur when local pathology (infection, tumor, infarction) triggers the release of inflammatory cytokines (like VEGF and histamine). This causes endothelial gap widening, allowing protein-rich fluid and cells to leak into the pleural space. Large effusions mechanically compress the underlying lung parenchyma (compressive atelectasis), reducing compliance and impairing gas exchange, leading to dyspnea.
Diagnostic Criteria & Guidelines
Diagnosis requires imaging confirmation of fluid, followed by thoracentesis. Light's Criteria classifies it as an EXUDATE if at least one of the following is present: Pleural fluid protein / Serum protein > 0.5; Pleural fluid LDH / Serum LDH > 0.6; Pleural fluid LDH > 2/3 the upper limit of normal for serum LDH.
For Transudates (e.g., CHF): Treat the underlying condition with aggressive diuresis (IV Furosemide 40-80 mg). For Uncomplicated Exudates (e.g., pneumonia): Targeted systemic antibiotics (e.g., Ceftriaxone 1g IV + Azithromycin 500 mg IV). Therapeutic thoracentesis (removal of up to 1.5L) is performed for immediate relief of severe dyspnea.
Second-Line & Adjunctive Therapy
For Complicated Parapneumonic/Empyema: Prompt placement of a tube thoracostomy (chest tube, e.g., 14F pigtail) for continuous drainage. For Malignant effusions: Indwelling pleural catheter (PleurX) or chemical pleurodesis using Talc (e.g., 4g sterile talc slurry) to obliterate the pleural space.
Surgical & Procedural Management
Video-Assisted Thoracoscopic Surgery (VATS) with decortication is indicated for loculated empyemas or trapped lung that fail conservative chest tube drainage or intrapleural fibrinolytics (tPA + DNase).
Patient Counseling & Advice
Explain that the procedure to drain the fluid (thoracentesis) provides quick relief but does not cure the problem; the fluid may return until the root cause (like heart failure or infection) is effectively treated.
Follow-Up & Monitoring Schedule
Repeat CXR or bedside ultrasound in 24-48 hours post-drainage to assess for fluid re-accumulation or pneumothorax. Continued monitoring of the underlying systemic disease.
Preventive Strategies
Vaccination against Pneumococcus and Influenza to prevent pneumonia. Optimization of medical therapy for heart failure.
Highly dependent on the etiology. Transudates from CHF have a fair prognosis if managed. Malignant effusions generally portend a poor prognosis, with a median survival of 3-12 months. Empyema carries a 15% mortality rate in the elderly.